DARAXONRASIB: Targeting KRAS Mutations in Cancer Treatment
Cancer research has entered a new phase with the development of DARAXONRASIB, a small-molecule inhibitor specifically designed to target KRAS mutations. These mutations occur in approximately 25% of all human cancers, making KRAS one of the most prevalent oncogenes in oncology. The emergence of DARAXONRASIB represents a critical advancement in precision medicine, offering hope for…
